Novo Nordisk and Eli Lilly reached deals to lower GLP-1 drug costs for Medicare and Medicaid patients under Trump’s new ...

COPENHAGEN (Reuters) -Shares in Novo Nordisk and Eli Lilly slipped on Friday after both agreed with the U.S government to ...

The Trump administration’s pact with drugmakers to lower the price of GLP-1 drugs could pave the way for millions more to ...

Eli Lilly CEO David Ricks, one of the key participants at the event, was speaking when the man who is reportedly a ...

Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some ...

For standard GLP-1 usage, Roslin said that patients are started with a low dose and titrated up to clinical effect. That ...

Eli Lilly's ( LLY) weight-loss drug, Mounjaro, has become the best-selling medication in India by value as of October, surpassing GSK's ( GSK) antibiotic, Augmentin, a Reuters report said.

Eli Lilly’s anti-obesity drug Mounjaro became India’s top-selling medicine in October, reflecting the growing demand for ...

The agreement will make insulin and obesity treatments more affordable through federal programmes and direct-to-patient ...

Ozempic, Wegovy, Zepbound and similar drugs may drop to $245 to $350 a month for eligible folks. The pricing applies to ...

The list prices of obesity drugs Wegovy and Zepbound are over $1,000, but that’s not necessarily what you pay.

The plan echoes an October moment when Trump floated a $150 target for Ozempic. Dr. Mehmet Oz, then on stage, cautioned it ...